Your session is about to expire
← Back to Search
Psilocybin for PTSD
Study Summary
This trial is investigating whether psilocybin, a psychedelic drug, can help people with PTSD who haven't responded to other treatments.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 95 Patients • NCT02061293Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a substance use disorder that could affect the goals of the study, such as drinking more than 5 cups of coffee with caffeine each day, being unable to go without smoking cigarettes or cannabis without feeling uncomfortable, or drinking alcohol within 7 hours before the study.You are afraid or uncomfortable with having blood drawn or getting injections with needles.You have been diagnosed with a personality disorder that significantly affects your mental health.Subjects must meet the following criteria to be eligible for enrollment into the study.You have been diagnosed with schizophrenia, bipolar disorder, or obsessive-compulsive disorder.You have a serious eating disorder where you engage in purging (vomiting) or have anorexia (severely restricted eating). Additionally, if you have had a significant and unhealthy weight change of 5kg in the last month, you will not be able to participate.Subjects must have treatment-resistant PTSD symptoms, defined as a CAPS score of ≥50 (signifying moderate to severe symptoms) following at least 3 months of prior SSRI or SNRI treatment in addition to at least 4 months of psychotherapy.You have medical or emotional conditions that could make it unsafe for you to participate in the study. For example, if you have uncontrolled diabetes, severe heart problems, seizures, untreated sleep apnea, or if you have shown signs of being untrustworthy or having suicidal thoughts.You have recently attempted suicide or have ongoing thoughts of wanting to harm yourself, as determined by the study staff.You have been receiving treatment for PTSD with medications called SSRIs or SNRIs, as well as therapy, for at least 3 months. However, your symptoms have not improved and you still have moderate to severe symptoms, as determined by a score of 30 or higher on a test called CAPS.You have used any experimental drugs, drugs that can cause hallucinations, or ketamine/esketamine in the past month or plan to use them during the study.
- Group 1: Psilocybin treatment for treatment-resistant PTSD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical research offering participation to individuals aged 25 and over?
"The lower limit of eligibility is 18, while the upper cap for admission has been set at 70."
Am I qualified to partake in this research endeavor?
"The prerequisites for enrolment in this research include moral injury and an age between 18-70. This experimental trial is limited to a maximum of 20 participants."
Is the administration of Psilocybin free from major hazards?
"Considering that we are in the second phase of this research, there is some evidence to suggest Psilocybin's safety; as such, it receives a score of 2."
Are there still opportunities to take part in this experiment?
"The clinicaltrials.gov website confirms that this trial is no longer enrolling patients, having been initially posted on October 3rd 2022 and last updated the same day. Despite not being able to participate in this particular research project, there are a plethora of other studies actively recruiting participants resulting in 1237 options currently available."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Most responsive sites:
- Halucenex Life Sciences Inc.: < 24 hours
Share this study with friends
Copy Link
Messenger